Nicholas Galakatos's Net Worth

$272 Million

Who is Nicholas Galakatos?

Nicholas Galakatos has an estimated net worth of $272 Million. This is based on reported shares across multiple companies, which include TETRALOGIC PHARMACEUTICALS Corp, EnteroMedics Inc, GLOBUS MEDICAL INC, COTHERIX INC, ZOGENIX, INC., ARYx Therapeutics, Inc., Restore Medical, Inc., CRYOCOR INC, VIACELL INC, HEMOSENSE INC, TERCICA INC, BARRIER THERAPEUTICS INC, Praxis Precision Medicines, Inc., RIGEL PHARMACEUTICALS INC, Radius Health, Inc., NanoString Technologies Inc, PHARMATHENE, INC, AVEO PHARMACEUTICALS INC, AERIE PHARMACEUTICALS INC, Talaris Therapeutics, Inc., Ophthotech Corp., Oxford Immunotec Global PLC, Sientra, Inc., XCYTE THERAPIES INC, PONIARD PHARMACEUTICALS, INC., KALOBIOS PHARMACEUTICALS INC, Entasis Therapeutics Holdings Inc., Restoration Robotics Inc, CATABASIS PHARMACEUTICALS INC, Forty Seven, Inc., CRITICAL THERAPEUTICS INC, AVANIR PHARMACEUTICALS, INC., Pharmasset Inc, Zalicus Inc., AFFYMAX INC, ACHILLION PHARMACEUTICALS INC, Somaxon Pharmaceuticals, Inc., PORTOLA PHARMACEUTICALS INC, HELICOS BIOSCIENCES CORP, SENORX INC, Alsius Corp, and METABASIS THERAPEUTICS INC.

SEC CIK

Nicholas Galakatos's CIK is 0001252522

Past Insider Trading and Trends

2013 was Nicholas Galakatos's most active year for acquiring shares with 36 total transactions. Nicholas Galakatos's most active month to acquire stocks was the month of May. 2004 was Nicholas Galakatos's most active year for disposing of shares, totalling 45 transactions. Nicholas Galakatos's most active month to dispose stocks was the month of May. 2010 saw Nicholas Galakatos paying a total of $28,129,182.13 for 20,757,820 shares, this is the most they've acquired in one year. In 2014 Nicholas Galakatos cashed out on 2,264,400 shares for a total of $70,587,309.17, their largest year based on trade value.